Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation

Clicks: 313
ID: 270181
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 15 articles by views in drugs & aging

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible …
Reference Key
pl2015drugslenalidomide: Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors McCormack PL;;
Journal drugs & aging
Year 2015
DOI
DOI not found
URL
https://www.pubmed.gov/25925941/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review animals clinical trials as topic humans pubmed abstract nih national institutes of health national library of medicine treatment outcome Angiogenesis Inhibitors / therapeutic use* prednisone / therapeutic use antineoplastic combined chemotherapy protocols / therapeutic use Melphalan / therapeutic use lenalidomide multiple myeloma / drug therapy* thalidomide / adverse effects thalidomide / analogs & derivatives* pmid:25925941 doi:10.1007/s40266-015-0269-6 paul l mccormack angiogenesis inhibitors / adverse effects angiogenesis inhibitors / pharmacology stem cell transplantation thalidomide / pharmacology thalidomide / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.